Intro to COVID-19: Defining Emergency Use Authorization (EUA) Authorities

This session will address general regulatory requirements for bringing a medical product to market under emergency use authorities in the Federal Food, Drug, and Cosmetic Act.

Cathy L. Burgess, Partner, Alston & Bird LLP,  Member, FDLI Board of Directors

This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues” in August 2020.

 

Get Access

$99
  • +$100 for nonmembers
Legal issues regarding the response to COVID-19 is a rapidly evolving field. It is important to note the program recording date given that FDA guidance may have revised or been updated. For questions, please check the FDA website at:  https://www.fda.gov/home

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

 

On-demand content can be played back on most devices.

If you have concerns, please click the Test Your System link to determine your device's compatibility, as well as system requirements. 

CLE credit is not currently available for pre-recorded sessions.

Related Content